Background: In the United Kingdom, 8,000 cases of renal cancer are diagnosed each year, with a 5-year survival rate of 50%. Treatment options are limited; a potential therapeutic target is the non-canonical nuclear factor-kappa B (NF-κB) pathway. This pathway plays a role in multiple oncogenic processes in solid tumors. The aim of this study was to investigate the non-canonical nuclear factor pathway in renal cell carcinoma (RCC). Materials and Methods: NIK, IKKα, and RelB were investigated via immunohistochemistry in a cohort of 192 patients with clear cell renal cancer. Results: High cytoplasmic NIK was associated with poorer cancer-specific survival (p = 0.006) and 10-year survival stratified from 85% (low) to 65% (high, p = 0.005). Similarly, high cytoplasmic RelB was associated with poorer cancer-specific survival (p = 0.041) and 10-year survival stratified from 88% (low) to 73% (high, p = 0.030). When clinicopathological characteristics were assessed, cytoplasmic NIK was associated with survival (p = 0.014), whereas cytoplasmic RelB was associated with increased tumor grade (p = 0.020) and decreased inflammation (p = 0.019). Upon multivariate analysis, it was found that cytoplasmic NIK was independently associated with cancerspecific survival (p = 0.009). Conclusions: The non-canonical NF-κB pathway is associated with poorer cancer-specific survival in RCC patients, making it a viable target for therapeutic intervention. Furthermore, cytoplasmic NIK is a potential prognostic biomarker for this disease.
Introduction
Renal cell carcinoma (RCC) is the 8th most common cancer in the United Kingdom with a 5-year survival rate of around 50% [1] . Incidence rates have been rising due to the development of modern imaging techniques for earlier cancer detection as well as a rise in risk factors such as smoking and obesity. Chemotherapy is largely ineffective as RCCs have high expression levels of the multi-drug resistance protein, P-glycoprotein. Commonly used modes of first-line systemic therapy include Sunitinib and Pazopanib (tyrosine kinase inhibitor), Bevacizumab (vascular endothelial growth factor inhibitor), interferon α (immunotherapy), and Temsirolimus (mammalian target of rapamycin inhibitor) [2] . The ineffectiveness of chemotherapy limits the number of available treatment options for patients, and thus research into pathways contributing to RCC tumorigenesis is necessary to identify drug targets and develop potential therapeutics.
Nuclear factor-kappa B (NF-κB) is a family of transcription factors that can act via either the canonical or non-canonical pathway. The non-canonical pathway activates NF-kappa-B-inducing kinase (NIK), which subsequently phosphorylates inhibitor of nuclear factor kappa-B kinase subunit alpha (IKKα). IKKα then phosphorylates p100, leading to ubiquitination of p100 and release of active p52:RelB dimers. The p52:RelB dimers can then translocate to the nucleus where they drive gene transcription [3, 4] . The functions of genes transcribed by NF-κB can be divided into 4 broad categories, immunoregulatory and inflammatory genes, anti-apoptotic genes, genes promoting cell proliferation, and negative regulators of NF-κB, all of which are important in RCC. It is also known that dysregulation of these target genes leads to tumorigenesis in a variety of cancers [5] .
The importance of the non-canonical pathway has been demonstrated in various types of solid tumors. In breast cancer, the non-canonical pathway can be activated via the receptor activator of nuclear factor kappa-Β ligand (RANKL). Either inhibiting RANKL or constitutive RANKL activation causes the elevation of NF-κB activity, which subsequently stimulates cell proliferation via increased transcription of cyclin D1 [5] . In glioblastoma, this pathway is implicated to cause a very aggressive subtype. In mouse xenografts, NIK was shown to cause changes in cell conformation, increasing invasive capacity of tumor cells [6] . Studies looking at the role of the non-canonical pathway in renal cells have also been performed, but have not specifically assessed RCC. In renal cells, Tumor Necrosis Factor-like Weak Inducer of Apoptosis (TWEAK) can activate the non-canonical NF-κB pathway to induce production of inflammatory mediators, as well as induction of apoptosis during kidney injury and cell proliferation [7, 8] . This pathway has been implicated in various renal diseases such as diabetic nephropathy, glomerular disease, and acute kidney injury, but its role in RCC is still unclear [9] .
Therefore, this study aimed to investigate the role of the non-canonical NF-κB pathway in clear cell RCC, using immunohistochemistry to assess protein expression of NIK, IKKα, and RelB. Expression was then correlated with patient survival and clinical outcome measures. 
Methods

Patient Cohorts
Immunohistochemistry
Immunohistochemical analysis of NIK, IKKα, and RelB was carried out using previously constructed clear cell RCC tissue microarray.
Sections were dewaxed in Histoclear and then rehydrated using graded alcohols. Antigen retrieval was performed using citrate buffer pH6 under pressure for 5 min before cooling for 20 min. Endogenous peroxidase activity was blocked using 3% hydrogen peroxide for 10 min. As a blocking solution, 5% horse serum (Vector Laboratories) for IKKα and RelB or 10% Casein for NIK were applied for 30 min at room temperature. Slides were incubated overnight at 4 ° C with IKKα (Genway), RelB (Cell Signaling Technology), and NIK (abcam) at concentrations of 1: 2000, 1: 100, and 1: 250 respectively. Envision (Dako) was added to the sections for 30 min at room temperature before washing in TBS. DAB substrate was added for 5 min until color developed before washing in running water for 10 min. Slides were then counterstained in hematoxylin for 60 s and blued with Scotts' tap water before being dehydrated through a series of graded alcohols. Cover slips were applied using distrene, plasticizer, and xylene.
Scoring
Stained tissue microarray sections were scanned using a Hamamatsu NanoZoomer (Welwyn Garden City, Hertfordshire, UK) at ×20 magnification and visualized on Slidepath Digital Image Hub (Leica Biosystems, Milton Keynes, UK). Assessment of NIK, IKKα, and RelB expression was performed by a single examiner (J.L.) blinded to clinical data at ×20 magnification (total magnification ×400) using the weighted histoscore [10] . The weighted histoscore is calculated as follows: 0x% not stained + 1x% weakly stained + 2x% moderately stained + 3x% strongly stained. This gives a range of scores from 0 to 300 and is calculated individually for nuclear, membrane, and cytoplasmic staining. To ensure reproducibility, 10% of tumors were co-scored by a co-investigator (J.E.).
Statistical Analysis
Statistical analysis was carried out using SPSS software. For all statistical analyses, the p value was set at < 0.05. Only patients with a score for IKKα, NIK, and RelB were included in the analysis (n = 174). The histoscores for NIK and IKKα where dichotomized using the median as the cut-off, whereas RelB was dichotomised using the lower quartile as the cut-off. The relationship between clinicopathological characteristics and protein expression was examined using the chi-square test for linear trend. The relationship between expression and cancer-specific survival was examined using the Kaplan-Meier method. The log rank test was utilized to compare significant differences between subset groups using univariate analysis. Multivariate cox regression analysis was performed to identify those factors that were independently associated with cancer-specific survival (CSS).
Results
The cohort consisted of 192 RCC patients of whom 135 were alive at the last follow-up, 36 died of RCC, and 20 died of other causes. The median age of diagnosis was 61 years. The length of follow-up ranged from 0.1 to 182 months, with a mean follow-up time of 74 months. Mean CSS was 35 months (range 0.1-98 months).
For this cohort, a tissue-microarray was utilized and expression of NIK, IKKα, and RelB was observed in the tumor cell membrane, cytoplasm, and nucleus respectively (Fig. 1) . Only patients with a score for all 3 proteins were included in the analysis (n = 174). Expression was divided into quartiles and the median used as the cut-off for low and high NIK and IKKα expression, whereas the lower quartile was used for RelB. The associations between protein expression and CSS are shown in Table 1 . Expression of IKKα at any location was not Fig. 2a ). Ten-year CSS was stratified from 85% (low) to 68% (high, p = 0.005). Similarly, cytoplasmic RelB was significantly associated with poorer CSS (p = 0.041, 11.9 vs. 11.9 years; Fig. 2b ). Ten-year CSS was stratified from 88% (low) to 73% (high, p = 0.030). Cytoplasmic NIK and RelB also significantly correlate, suggesting that they are both acting as part of the non-canonical pathway (p < 0.001; Table 2 ). Trends toward poorer CSS were also seen for membrane NIK (p = 0.057; 13.2 vs. 11.3 years) and membrane IKKα (p = 0.132, 12.9 vs. 11.6 years). Again, membrane NIK strongly correlates with cytoplasmic NIK (p < 0.001) and RelB (p < 0.001; Table 2) . Similarly, membrane IKKα shows associations with cytoplasmic RelB (p = 0.084; Table 2 ). Interestingly, nuclear RelB showed a slight trend toward associations with poorer CSS (p = 0.306, 12.8 vs. 12.2 years) and strongly correlated with both cytoplasmic NIK and RelB (p < 0.001; Table 2 ). This suggests that pathway is active in RCC and NIK can modulate the pathway to translocate RelB to the nucleus to promote tumorigenesis. The relationship between cytoplasmic NIK, RelB, and clinicopathological characteristics were then examined (Table 3) . Cytoplasmic NIK only associated with increased CSS (p = 0.014), whereas cytoplasmic RelB associated with increased grade (p = 0.020), decreased Klintrup-Makinen grade (p = 0.019), and trended toward associations with increased CSS (p = 0.079). 
Discussion
This study shows that the non-canonical NF-κB pathway is associated with poor prognosis in RCC. Specifically, high cytoplasmic NIK and RelB are significantly associated with poor CSS, with membrane NIK/IKKα as Values in bold reached statistical significance. These results are similar to other studies that show NIK is a tumorigenic factor. In ovarian cancer cells, NIK has been shown to increase cell growth and tumorigenicity. In multiple myeloma, it has been proposed that tumorigenesis depends upon NIK-driven p100/52 activation promoting B-cell survival [11] . NIK has also been shown to be a poor prognostic factor for glioblastoma [6] . Similarly, RelB has also been shown to be a poor prognostic factor in many solid tumors. In non-small cell lung cancer, RelB is associated with shorter overall survival, poorer differentiation, tumor invasion, lymph node metastasis, distant metastasis, and TNM stage [12] . In ER +ve breast cancer, RelB and p52 were inversely correlated with ER levels and associated with poorer diseasefree survival [13] . In bladder cancer, RelB and p52 levels have been shown to be increased in cancer tissue compared to normal bladder. Both RelB and p52 were also shown to be correlated with histological grade, stage, and lymph node metastasis, suggesting that the non-canonical pathway promotes bladder cancer [14] .
Little is known about the role of the non-canonical pathway in renal disease including RCC. RelB has been shown to play a role in lymphocyte recruitment during acute kidney injury when activated by TWEAK [15] . RelB has also been shown to play a role in renal ischemia-reperfusion injury (IRI). Silencing of RelB in a mouse model of IRI significantly attenuated IRI-induced renal dysfunction, with RelB silenced mice having a significant survival advantage [16] . However, literature on the effects of the non-canonical NF-κB in RCC is lacking. One study shows that the non-canonical pathway is downregulated in von Hippel-Lindau disease (VHL)-negative RCC cell lines and this results in diminished monocyte cell adhesion [17] . However, in this study, we show that high expression of cytoplasmic NIK and RelB is associated with the downregulation of the local inflammatory infiltrate and poor prognosis, with cytoplasmic NIK being an independent prognostic factor for these patients. Overall, this suggests that non-canonical pathway may be a potential therapeutic target for RCC.
To date, the inflammatory effects of the NF-κB pathway have mainly been attributed to the canonical p65/p50 subunit in conjunction with STAT3. However, NIK and RelB have previously been shown to be crucial for B-cell development [18] , suggesting that the non-canonical pathway also plays a role. The study also provides evidence that RelB can modulate the local inflammatory infiltrate in RCC patients.
Conclusion
In conclusion, the results of this study indicate that the non-canonical NF-κB pathway is associated with poorer RCC patient prognosis through NIK and RelB. The study suggests that NIK regulates RelB activation, which in turn downregulates the local inflammatory infiltrate to facilitate tumor progression. Therefore, NIK may be a useful prognostic biomarker for this disease and both NIK and RelB may be potential therapeutic targets.
